Skip to main content
. 2019 Sep 20;9:904. doi: 10.3389/fonc.2019.00904

Figure 3.

Figure 3

ITGB5 overexpression is a prognostic biomarker in GBM. (A–F), Kaplan-Meier analysis of the association between ITGB5 expression and patient survival according to glioma grade (A, CGGA grade II; B, CGGA grade III; C, CGGA grade IV; D, TCGA grade II; E, TCGA grade III; F, TCGA grade IV). (G) Kaplan-Meier analysis of the correlation between high ITGB5 expression and patient prognosis in GBM (ITGB5 high vs. low, P = 0.0042; log-rank test). (H–K) Results of the Kaplan-Meier analysis demonstrating that high ITGB5 expression is associated with poor survival in GBM patients receiving radiotherapy (H, CGGA RNAseq; I, TCGA RNAseq) or chemotherapy (J, CGGA RNAseq; K, TCGA RNAseq). ns, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001 (log-rank test).